ImageneBio, Inc.: Blue Owl Capital Holdings LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Blue Owl Capital Holdings LP amended its Schedule 13G filing on ImageneBio, Inc., updating its beneficial ownership stake with the SEC under accession number 0001140361-26-043771. The amendment signals a change in the investment firm's position in the clinical-stage biopharmaceutical company, though the filing did not disclose specific share counts or percentage moves in the headline. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts relative to the 5% threshold, making the update relevant for tracking institutional interest in ImageneBio. Investors should watch for the full filing details to confirm whether Blue Owl increased, trimmed or maintained its stake, and whether the change reflects index or fund-level rebalancing rather than a directional bet.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Blue Owl Capital Holdings LP, ImageneBio, Inc.